Charles Schwab Investment Management Inc Tcr2 Therapeutics Inc. Transaction History

Charles Schwab Investment Management Inc

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$1.0 - $1.62 $22,638 - $36,673	22,638 New	22,638 $33,000
Q2 2022 Aug 15, 2022	SELL	$2.11 - $2.94 $106,445 - $148,317	-50,448 Reduced 22.17%	177,081 $514,000
Q1 2022 May 13, 2022	SELL	$2.4 - $4.71 $18,537 - $36,380	-7,724 Reduced 3.28%	227,529 $628,000
Q4 2021 Feb 11, 2022	BUY	$4.58 - $8.34 $14,665 - $26,704	3,202 Added 1.38%	235,253 $1.1 Million
Q3 2021 Nov 16, 2021	BUY	$8.44 - $18.35 $316,331 - $687,758	37,480 Added 19.26%	232,051 $1.98 Million
Q2 2021 Aug 16, 2021	BUY	$16.41 - $24.71 $107,567 - $161,974	6,555 Added 3.49%	194,571 $3.19 Million
Q1 2021 May 17, 2021	BUY	$20.38 - $34.07 $579,383 - $968,576	28,429 Added 17.81%	188,016 $4.15 Million
Q4 2020 Feb 16, 2021	BUY	$19.0 - $32.63 $14,801 - $25,418	779 Added 0.49%	159,587 $4.94 Million
Q3 2020 Nov 13, 2020	BUY	$13.1 - $20.69 $801,182 - $1.27 Million	61,159 Added 62.63%	158,808 $3.23 Million
Q2 2020 Aug 14, 2020	BUY	$6.51 - $16.85 $107,043 - $277,064	16,443 Added 20.25%	97,649 $1.5 Million
Q1 2020 May 15, 2020	BUY	$6.01 - $16.01 $10,733 - $28,593	1,786 Added 2.25%	81,206 $629,000
Q4 2019 Feb 07, 2020	BUY	$12.17 - $17.88 $11,999 - $17,629	986 Added 1.26%	79,420 $1.14 Million
Q3 2019 Nov 08, 2019	BUY	$10.15 - $19.53 $548,810 - $1.06 Million	54,070 Added 221.93%	78,434 $1.18 Million
Q2 2019 Aug 09, 2019	BUY	$13.64 - $20.97 $332,324 - $510,913	24,364 New	24,364 $349,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.